The Recall Desk
HighFDA (Drugs)·D-0654-2024·Announced 2024-09-11

ProRx Compounded Semaglutide/Cyanocobalamin Injection Recalled Due to Sterility Assurance Issues

ProRx LLC is recalling 500 vials of compounded Semaglutide/Cyanocobalamin Injection (Lot #ProRx031924-1) distributed nationwide in the United States due to lack of sterility assurance. The beyond-use date is 09/18/2024.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall of a compounded injectable medication due to inability to assure sterility standards. This represents a risk-of-harm product where no illnesses have been reported, meeting the criterion for High severity.

Plain-English summary

ProRx LLC is recalling one lot of compounded Semaglutide/Cyanocobalamin Injection (2.5/0.5 mg/mL, 2 mL multiple-dose vials) distributed nationwide in the United States. The recalled product is Lot #ProRx031924-1 with NDC 84139-225-02 and beyond-use date of 09/18/2024, affecting 500 vials.

The recall is issued because the manufacturer cannot assure that the compounded product meets sterility standards.

Patients and healthcare providers who have this medication should contact their healthcare provider or pharmacist for guidance.

The recalled product

Product
Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02
Manufacturer
ProRx LLC
Hazard
  • sterility

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # ProRx031924-1
  • BUD 09/18/2024

Distribution

Distributed nationwide across the United States.